ASI Webinar: Digital Solutions for PD-L1 Interpretation
When: Wed, Jun 6, 2018 10:00 AM – 11:00 AM PDT
Register Now
PD-L1 is seen as the current breakthrough therapeutic target in immuno-oncology. Following recent clinical advances, PD-L1 expression has become a key factor in determining the treatment for patients with non-small cell lung cancer (NSCLC), the most common type of cancer which accounts for 13% of the total number of cancer cases in the US. The significant success of PD-1/PD-L1 blockades in lung cancer has led to the FDA approval of revolutionary immunotherapy drugs, and PD-L1 assays are becoming standard care for all patients with a suspected lung cancer.
As an early adopter of the PD-L1 immunostain methodology, Dr. Lija Joseph and her team at Lowell General Hospital, quickly recognized the inter and intra observer variability in scoring and interpretation of the stain, especially when there is non-uniform staining among tumor regions.
Join us as Dr. Joseph presents results of a comparison study between manual and computer-aided analysis for the scoring of PD-L1 in non-small cell lung cancer (NSCLC) tissue samples. Digital interpretation was found to overcome manual sampling errors and insufficient cell-count and improved the accuracy and precision of the interpretation.
Presented by
Dr. Lija Joseph
Medical Director, Department of Pathology and Laboratory Medicine, Lowell General Hospital
